By Iain Gilbert
Date: Monday 14 Sep 2026
(Sharecast News) - Drugmaker GSK reported two major advances in its oncology pipeline on Monday, as new data showed its B7‑H3 antibody‑drug conjugate Ris‑Rez delivered a significant survival benefit in relapsed small cell lung cancer, while registrational results for Jideytro supported a potential move into first‑line ROS1‑positive non‑small cell lung cancer.
By Iain Gilbert
Date: Thursday 10 Sep 2026
(Sharecast News) - Drugmaker GSK said on Thursday that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe version of its shingles vaccine Shingrix, offering a simpler, ready‑to‑use presentation for healthcare professionals.
By Iain Gilbert
Date: Tuesday 01 Sep 2026
(Sharecast News) - Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III after reporting positive Phase II results at the OPTIONS XIII influenza conference.
| Currency | UK Pounds |
| Price | 1,864.00p |
| Change Today | 9.50p |
| 52 Week High | 2,208.00p |
| 52 Week Low | 1,470.50p |
| Volume | 115,521 |
| Shares Issued | 4,045.42m |
| Market Cap | £75,407m |